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Background: Neuroendocrine prostate cancer is rare but lethal. It is one of the most common extra
pulmonary manifestations of small cell cancer.
Case presentation: Here we present a case report of a 53-year-old male who presents with a mixed
adenocarcinoma and neuroendocrine prostate tumor on a background of previously normal prostate-specific
antigen (PSA). His initial symptoms prior to diagnosis included decreased urine output and acute kidney
injury (AKI).
Conclusion: Neuroendocrine tumor does not elevate the PSA level and hence is often a late finding with a
poor prognosis. Special staining on histopathogy is required to reveal this diagnosis.
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euroendocrine prostate cancer was first de-
scribed approximately 40 years ago, but remains
a poorly understood entity. Prostate-specific
antigen (PSA) levels are unreliable markers of disease
activity and may remain low despite advanced obstructive
symptoms, thereby fostering a false sense of security
among care providers. With this case report, we hope to
highlight key clinical features of neuroendocrine prostate
cancer.
Case report
A 53-year-old male with a previous history of minimal
prostatic hypertrophic symptoms and benign exam initi-
ally presentedwith productive cough, shortness of breath,
andfevers.Afterfailingtoimprovewithtworoundsoforal
antibiotics, a chest x-ray was performed and revealed
bilateralmultifocalpneumonialeadingtoadmissiontothe
hospital. On admission, he incidentally noted decreased
urinary output for several days, and was found to have
acute kidney injury (AKI) (creatinine 5.25 mg/dL, base-
line 1.03 mg/dL), as well as a profound anemia with no
significant bleeding site identified (Hgb 5.1 g/dL). Renal
ultrasound revealed a right-sided hydronephrosis. Digital
rectalexamwaspositiveforagrosslyirregular,firm,nodu-
lar prostate suspicious for aggressive prostate cancer. Due
to AKI, a computed tomography (CT) urogram was not
possible; however, urine cytology showed evidence of
atypical cells and microscopic hematuria. Non-contrast
CT scan of the abdomen and pelvis showed evidence of
sclerotic bony lesions suggestive of metastatic disease. In
addition, his PSA which 7 months earlier was 1.9 ng/mL
had risen to 119.69 ng/mL. Biopsy was refused by the
patient,hispulmonarysymptomsresolved,andthepatient
was subsequently discharged and lost to follow-up for
2 months. He thenpresentedto the emergencydepartment
withurinary retention andproductivecoughand dyspnea.
At that time, he had progressed to bilateral hydronephro-
sis with obstruction despite routine self-catheterization
and required bilateral nephrostomy placement. Prostate
biopsy revealed concurrent small cell carcinoma (SCC)
of the prostate and a minor component of high-grade
adenocarcinoma, Gleason (34) (Figs. 13). Positron
emission tomography (PET) scan showed evidence of
metastasis to bone (Fig. 4), with the largest most hyper-
metabolic foci in the left scapula, left iliac wing and lymph
nodesofthethorax andlung. CTscanshowed mediastinal
lymphadenopathy with a right middle lobe opacification
concerning for post bronchial obstruction (Fig. 5). Trans-
bronchial biopsy revealed small cell anaplastic carcinoma.
He was immediately started on cisplatin and etoposide
for the neuroendocrine component, aswell as Lupron and
Bicalutamide for the adenocarcinoma component.
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Neuroendocrine prostate cancer, also known as small
cell cancer of the prostate, was first reported in 1977 (1).
Extrapulmonary sites of small cell carcinoma account for
approximately 11% of total small cell cancer presenta-
tions, with 3% of these presenting first in the prostate
(2). In total, these cancers represent less than 1% of all
prostatic cancers (3). It is one of the more common sites
for extra pulmonary manifestation of small cell cancer
with approximately 10% extra pulmonary cases noted to
be in the prostate gland. An under recognized clinical
condition, it has an overall poor prognosis as it is aggres-
sive with early metastasis and is poorly responsive to
chemotherapy regimens (4).
Presenting complaints are generally related to obstruc-
tion, with difficulty urinating and hematuria being
especially common (5). Our patient presented with acute
renal failure secondary to an obstructive uropathy and
anemia with an Hb of 5.1 g/dL. PSA is an unreliable
marker and can remain low unless the neuroendocrine
carcinoma is present along with another more common
prostatic adenocarcinoma (5). Over the course of 7
months, this patient went from a benign prostate exam
with a PSA of 1.9 ng/dL to a grossly abnormal exam and
a PSA of 119.69 ng/dL, testifying to the aggressive nature
of the disease process. Metastatic disease of the adeno-
carcinoma was present at the time of diagnosis (the bony
metastases) and was the more likely cause of the PSA
elevation.
The origin of small cell prostate cancer is largely
unknown with some authors of the opinion that it is a
dedifferentiation of an aggressive adenocarcinoma that
can result in extensive and frequently terminal disease.
Beltran et al. (6) indicate that neuroendocrine cells are
responsible for hormonal therapy resistant prostate
cancer, which allows some prostate adenocarcinomas to
completely escape androgen blockade and become hor-
mone refractory. Some authors have documented this as a
dedifferentiation of a typical prostatic adenocarcinoma
as the disease progresses, thus representing an aggressive
and often terminal phase of this disease. In these situa-
tions, a neuroendocrine component has been found in
10100% of prostate cancer cases (7, 8). A postulated
competing theory is that the neuroendocrine component
originates from malignant transformation of normal
prostatic cells or even pluripotent epithelial cells, thereby
causing unpredictable differentiation (9, 10). A third
theory postulates that the origin of this type of malig-
nancy is directly from stem cells, given its immunohisto-
chemical features, low PSA levels, androgen receptor
positivity and very high MIB-1 index (2). Postulates 2
and 3 might explain the presentation in our patient with a
normal PSA less than a year before he was diagnosed with
small cell prostate carcinoma. Immunohistochemistry
can be useful in identifying this malignancy, with CD-56
staining positive in 92% of cases and synaptophysin posi-
tive in 85% of cases, which is helpful in discriminating
Fig. 1. Racemase stain (arrow) highlighting Gleason (34)
adenocarcinoma.
Fig.2. CD-56stainhighlighting areasof small cellcarcinoma
(area stained brown is positive for CD-56).
Fig. 3. Synaptophysin statin highlighting areas of small cell
carcinoma (area staining brown is positive for SCC).
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noma (Gleason 5) (11).
The median overall survival time is approximately 13
months (12, 13). At the time of diagnosis, hyponatremia,
non-genitourinary extrapulmonary small cell cancer, exten-
sive disease, elevated serum lactate dehydrogenase (LDH),
low serum albumin and older age at presentation are as-
sociated with poorer prognosis in these patients (1214).
One case with a mixed adenocarcinoma and neuroendo-
crine small cell carcinoma with extensive disease has been
reported with remission up to 36 months with aggressive
hormonal and chemotherapy (six cycles of etoposide,
cisplatin 100 mg/m
2) and radiotherapy to pelvis and lymph
nodes (15). Stein et al.’s retrospective study of 30 patients
with prostate SCC revealed only one patient who re-
mained in remission for 54 months post-chemo radiation
therapy (5). No correlating factors were found. However,
in that case the lung metastasis was of adenocarcinoma
origin, which might explain the prolonged disease free
period. However, our patient was noted to have small cell
carcinoma on lung biopsy which is likely to have a
negative effect on his overall prognosis.
Molecular characterization of this malignancy has re-
vealed overexpression and amplification of the AURKA
and MYCN (16, 17). Both invivo and invitro studies have
shown promising results with Aurora Kinase inhibitor
therapy (16); however, these are still at an experimental
stage and not available to patients at this time.
Conclusion
Extrapulmonary SCC is a rare but often fatal etiology
of prostate cancer with an overall bleak prognosis and no
Fig. 4. (a) PET CT showing hypermetabolic lesions in L scapula and L Iliac wing suggestive metastatic disease (solid arrows).
(b) PET CT in in coronal section showing hyper lucent lesion in L scapula; note the absence of PET CT ﬁndings in lung tissue
which is pathognomonic of neuroendocrine tumors.
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chemo and radiation therapy and the treatment protocol
often mimics that of small cell cancer of the lung. It is
important for clinicians to remember that this aggressive
form of prostate cancer is not detectable with PSA studies
and there are no other early detection modalities available
at this time. Additionally, these tumors often have features
that make it arduous for surgical pathologists to identify
it, thus making it a diagnostic dilemma for clinicians.
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Fig. 5. (a) Represents a non-contrast CT scan (mediastinal window) with arrow showing paratracheal lymphadenopathy and
(dashed arrow) showing R sided pleural effusion. (b) CT scan showing R sided opaciﬁcation with concern for pneumonia vs.
post bronchial obstruction and concern for malignancy (this was the lesion that was biopsied).
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